Φορτώνει......

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) pl...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Oncol
Κύριοι συγγραφείς: Patel, Jyoti D., Socinski, Mark A., Garon, Edward B., Reynolds, Craig H., Spigel, David R., Olsen, Mark R., Hermann, Robert C., Jotte, Robert M., Beck, Thaddeus, Richards, Donald A., Guba, Susan C., Liu, Jingyi, Frimodt-Moller, Bente, John, William J., Obasaju, Coleman K., Pennella, Eduardo J., Bonomi, Philip, Govindan, Ramaswamy
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2013
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881367/
https://ncbi.nlm.nih.gov/pubmed/24145346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.9626
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!